Cynapsus Therapeutics to Present at Several Upcoming Investor Conferences

TORONTO, April 28, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson’s disease (“PD”), today announced that senior management will present a corporate overview at the following upcoming investor conferences:

  • Bloom Burton & Co. HealthCare Investor Conference on May 2, 2016 at 10:00 a.m. ET at the Sheraton Centre Hotel in Toronto
  • Deutsche Bank Securities 41st Annual Health Care Conference on May 4, 2016 at 11:20 a.m. ET at the InterContinental Hotel in Boston
  • Bank of America Merrill Lynch 19th Annual Health Care Conference on May 12, 2016 at 11:20 a.m. PT at the Encore at Wynn Hotel in Las Vegas

Additional details and live webcasts of Cynapsus’ presentations at the Deutsche Bank and Bank of America Merrill Lynch conferences may be accessed from the Company’s website at Replays of the webcasts will be available on Cynapsus website following the live presentation until August 4, 2016.

About Cynapsus

Cynapsus is a specialty central nervous system pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD. The Company has successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes, often considered the most difficult to treat. Cynapsus has initiated its Phase 3 clinical program for APL-130277, relying on the abbreviated Section 505(b)(2) regulatory pathway in the United States, and the Company intends to submit an NDA near the end of 2016 or in early 2017. For additional company information, please visit our website For more information about the Phase 3 studies, including enrollment criteria, please visit the website found here

Forward-Looking Statements

This announcement contains "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, the Company’s intention of submitting an NDA near the end of 2016 or early in 2017. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These forward-looking statements are based on the Company’s current expectations and beliefs and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ from those anticipated in such forward-looking statements as a result of risks and uncertainties, and include, but are not limited to, those factors identified under the caption “Risk Factors” in the Company’s Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 9, 2016, as amended by Amendment No. 1 to Form 10-K/A filed with the SEC on March 18, 2016, and its other filings and reports in the United States with the SEC available on the SEC’s web site at, and in Canada with the various Canadian securities regulators, which are available online at Furthermore, unless otherwise stated, the forward-looking statements contained in this press release are made as of the date of this press release, and the Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes or otherwise, except as required by law. 

Neither the NASDAQ nor the TSX has approved or disapproved of the contents of this press release.

Contact Information Cynapsus Therapeutics, Inc. Kristen Galfetti Vice President Investor Relations & Corporate Communications (416) 703-2449 x246 Media Contact: Russo Partners LLC Matt Middleman (212) 845-4272

Source:Cynapsus Therapeutics Inc.